Modality
Gene Editing
MOA
EGFRi
Target
PSMA
Pathway
Ferroptosis
Heart FailureDLBCLMigraine
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
Mar 2019
→ Jun 2027
Phase 1Current
NCT07702964
1,611 pts·Migraine
2019-03→2027-06·Not yet recruiting
NCT05469564
313 pts·DLBCL
2025-09→2025-10·Active
1,924 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-016mo agoInterim· DLBCL
2027-06-181.2y awayInterim· Migraine
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1
Not yet…
P1
Active
Catalysts
Interim
2025-10-01 · 6mo ago
DLBCL
Interim
2027-06-18 · 1.2y away
Migraine
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07702964 | Phase 1 | Migraine | Not yet recr... | 1611 | PASI75 |
| NCT05469564 | Phase 1 | DLBCL | Active | 313 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET |